1. Introduction {#sec1}
===============

The *α*-ketoacid dehydrogenase complexes comprise a unique family of large multienzyme structures, including the pyruvate-, *α*-ketoglutarate-, and branched-chain *α*-ketoacid dehydrogenase complexes and the related glycine decarboxylase complex \[[@B1]--[@B5]\]. These complexes have molecular mass values from 4 to 9 MDa and are among the largest non-viral protein assemblies. All family members have multiple copies of three central enzymes: E1, an *α*-ketoacid decarboxylase/dehydrogenase; E2, a dihydrolipoyl acyltransferase; E3, a dihydrolipoyl dehydrogenase. The overall reaction converts the *α*-ketoacid, NAD^+^, and reduced coenzyme A to CO~2~, NADH, and an acyl-CoA. The complexes are defined by their *α*-ketoacid specificity.

In prokaryotic cells the *α*-ketoacid dehydrogenase complexes are localized in the cytoplasm, while in eukaryotic cells they are within the mitochondrial matrix. Plant cells have a second form of the pyruvate dehydrogenase complex (PDC) which is localized within the plastid stroma \[[@B1], [@B2]\]. In addition to subcellular compartmentation, the activities of all of the complexes are regulated by product inhibition. The branched-chain *α*-ketoacid dehydrogenase complexes (BCKDCs) and mitochondrial PDCs are additionally regulated by reversible phosphorylation, mediated by intrinsic E1-kinases \[[@B1]--[@B3], [@B6]\] and P-E1-phosphatases \[[@B6], [@B7]\].

The PDC E1*α* active-site loop includes two (sites 1 and 2) of the three phosphorylation sites present in mammalian PDC ([Figure 1](#fig1){ref-type="fig"}). Plant PDC E1*α* sequences include a conserved Ser residue corresponding to mammalian phosphorylation site 1 and a Ser residue one position upstream of site 2. The Asp295 residue, conserved in both PDC and BCKDC E1*α* subunits, is located three residues from phosphorylation site 1. The results from studies using peptide substrates indicate that this residue is important for phosphorylation of E1 at site 1, and it has been proposed to be involved with PDK binding \[[@B8]\]. The Gly297 residue is conserved only in forms of PDC E1 that are phosphorylated, and there is a corresponding Ser residue in the BCKDC E1*α* sequences. This suggests that a small residue in this position is required for an appropriate conformation of the active-site loop for E1 phosphorylation.

Limited proteolysis has been used to probe the reaction mechanism of the dehydrogenase/decarboxylase (E1) component of mammalian *α*-ketoacid dehydrogenase complexes \[[@B9]--[@B12]\]. In all cases, loss of catalytic activity resulted from cleavage of the E1*α* subunit, while E1*β* remained unaffected. Limited proteolysis of *Bacillus stearothermophilus* PDC revealed that it is the surface loop of the E1*α* subunit structure that is susceptible to cleavage \[[@B13]\]. In the crystal structures of the BCKDC E1 from *Pseudomonas putida* \[[@B14]\] and *Homo sapiens* \[[@B15]\] and of the PDC E1 from *H. sapiens* \[[@B16]\], it is clear that this loop lies in the funnel-shaped active site formed by the E1*α* and E1*β* subunits and is 20--25 Å from the binding site of the thiamine pyrophosphate cofactor. The primary sequence of the active-site loop is conserved among plant and mammalian PDC E1 proteins, and, while sequence conservation with BCKDC is less, both loops have a similar structure \[[@B15], [@B16]\] suggesting that the individual residues (conserved or variable) perform the same biochemical function.

Site-directed mutagenesis of the active-site loop from mammalian PDC E1*α* highlighted the roles of Arg267 in binding the carboxyl group of pyruvate and Asp276, Tyr281, and Arg282 in both decarboxylation of pyruvate and the subsequent reductive acetylation of the lipoyl domains of E2 \[[@B17]\]. In addition, Ala scanning mutagenesis of the active-site loop of RnBCKDC E1*α* provided evidence that Arg288, His292, and Asp296 are also involved in catalysis \[[@B18], [@B19]\]. Moreover, the clinically deleterious H263L and R273C mutations of HsPDC E1*α* result in greatly reduced PDC activity \[[@B20], [@B21]\]. These residues correspond to Arg287, His291, Asp295, Tyr300, and Arg301 of the *Arabidopsis thaliana* PDC E1*α* (AtPDC E1*α*) sequence ([Figure 1](#fig1){ref-type="fig"}).

To better understand the catalytic mechanisms and regulatory properties of the plant mitochondrial PDC, it was necessary to develop a method to produce the recombinant enzyme that is both soluble and correctly assembled into the *α*2*β*2 heterotetramer. Previous attempts to use *Bacillus subtilis* \[[@B22]\] and *Pichia pastoris* \[[@B23]\] expression systems were plagued by problems with protein solubility and stability and codon usage bias. Herein, we describe a two-plasmid approach for expression of catalytically active heterotetrameric AtPDC E1 in *Escherichia coli*. Using a minimum *in vitro* assay system of recombinant AtPDC E1 and AtPDK, we have begun detailed analyses of the reversible phosphorylation of E1. We verified that the Ser residue corresponding to mammalian site 1 is a site of regulatory phosphorylation. Additionally, we targeted Asp295 and Gly297, residues conserved in the active-site loop but not previously tested for their contribution(s) to the catalytic activity of E1, and role(s) in phosphorylation-site recognition by PDK. Our results suggest that Asp295, but not Gly297, is involved in both E1 catalysis and phosphorylation.

2. Experimental Procedures {#sec2}
==========================

2.1. Plasmid Construction {#sec2.1}
-------------------------

A two-plasmid system was used for expression of AtPDC E1. Primers DDR321 and 322 (see Table S1 in Supplementary Material available online at doi:10.4061/2011/939068) were used to amplify the AtPDC E1*α* reading frame \[[@B24]\]. The DDR321 primer includes a NdeI site, a H~6~-affinity tag, and starts with S18 of E1*α*, the first residue after the N-terminal mitochondrial targeting sequence. The PCR product was cut with NdeI and XhoI, then ligated with similarly digested pT7-7 \[[@B25]\], yielding pDDR-E1*α*.

Similarly, primers DDR323 and 324 (Table S1) were used to amplify the AtPDC E1*β* reading frame \[[@B26]\]. The DDR323 primer includes a NcoI site, the FLAG epitope (DYKDDDDK) \[[@B27]\], and starts with A30 of E1*β*, the first residue after the N-terminal mitochondrial targeting sequence. The PCR product was digested with NcoI and HinDIII, then ligated with similarly digested pET28 (Novagen, Madison, WI, USA), yielding pDDR-E1*β*.

2.2. Protein Expression and Purification {#sec2.2}
----------------------------------------

The *E. coli* BL21 (DE3) host cells (Novagen, Madison, WI, USA) were sequentially transformed to express the GroE chaperonins \[[@B28]\], AtPDC E1*β*-pET28, and finally AtPDC E1*α*-pT7-7. Protein expression was induced by adding IPTG to a final concentration of 0.1 mM. Individual transformants were screened for high-level expression of soluble AtPDC E1. Cell growth, lysis, and affinity purification of recombinant AtPDC E1 and AtPDK are described elsewhere \[[@B29]\].

2.3. Size-Exclusion Chromatography {#sec2.3}
----------------------------------

Assembly of heterotetrameric AtPDC E1 was determined by size-exclusion chromatography. A Superose 12 column (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was equilibrated with 50 mM TES-NaOH, pH 7.4, containing 50 mM NaCl, 0.1 mM TPP, and 0.2 mM MgCl~2~. Column fractions were analyzed by SDS-PAGE, and the AtPDC E1 subunits were detected by immunoblotting \[[@B30]\]. The E1*α* monoclonal antibodies have been previously described \[[@B31]\]. Anti-FLAG antibodies were from the Sigma Chemical Co. (St. Louis, MO, USA).

2.4. Site-Directed Mutagenesis {#sec2.4}
------------------------------

Site-directed mutagenesis of AtPDC E1*α* was accomplished using the QuikChange kit from Stratagene (La Jolla, CA, USA). The S292D/S298A double mutant was constructed by preparing the S298A mutant first, then using it as the template for a second round of mutagenesis. The mutagenic primer pairs were DDR162 and DDR163 (S292A), DDR431 and DDR432 (S298A), DDR425 and DDR426 (S292D), DDR444 and DDR445 (G297S), DDR446 and DDR447 (G297D), DDR448 and DDR449 (D295N), DDR450 and DDR451 (D295A), and DDR452 and DDR453 (D295L) (Table S1). All mutations were verified by DNA sequencing.

2.5. Far-UV Circular Dichroism Spectroscopy {#sec2.5}
-------------------------------------------

The various expressed E1 proteins were examined by far-UV CD spectroscopy using an AVIV Model 202 spectrometer (Piscataway, NJ, USA) to determine if the site mutations introduced any significant perturbation in AtPDC E1 structure. Samples were analyzed at room temperature using a 0.1 cm path-length cuvette, and spectra were recorded from 190 to 300 nm at 1 nm intervals with a bandwidth of 1 nm. For each analysis, 200 *μ*L of purified protein in 20 mM KH~2~PO~4~/K~2~HPO~4~ (pH 7.4) at a concentration of 100--200 *μ*g/mL was used.

2.6. Phosphorylation of AtPDCE1 {#sec2.6}
-------------------------------

Phosphorylation was determined by measuring the incorporation of \[^32^P\] from \[*γ*-^32^P\]ATP (6000 Ci/mmole, Perkin-Elmer, Boston, MA, USA) into AtPDC E1. Recombinant E1 (1 *μ*g) was mixed with recombinant AtPDK (0.25 *μ*g) and kept for 30 min on ice. Reactions were conducted at 30°C in 20 mM TES-NaOH, pH 7.4, containing 5 mM MgCl~2~, 50 mM KCl, and 0.2 mM total ATP. Reactions were terminated after 90 min by adding 1/5 volume of 5x SDS-PAGE sample buffer (15% (w/v) SDS, 15% (v/v) 2-mercaptoethanol, 50% (v/v) glycerol). Proteins were resolved by SDS-PAGE, electroblotted to nitrocellulose, and examined by autoradiography. The incorporation of radiolabel into AtPDC E1 was quantified by liquid-scintillation spectrometry of the bands excised from Ponceau S stained membranes.

2.7. Peptide Mass Mapping of Phosphorylated E1*α* by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry {#sec2.7}
---------------------------------------------------------------------------------------------------------------------------------

The AtPDC E1*α* S298A mutant was phosphorylated by AtPDK using nonradioactive ATP. After SDS-PAGE, the AtPDC E1*α* band was excised and subjected to in-gel tryptic digestion. Desalted tryptic peptides in acetonitrile/water/88% formic acid (700/290/10, V/V/V) were applied to a 96x2 hydrophobic stainless steel target and topped with an equal volume of a 10-mg/mL solution of alpha-cyano-4-hydroxycinnamic acid (Fluka, St. Louis, MO, USA) in acetonitrile/water/10% trifluoroacetic acid (600/370/30, V/V/V). The sample and matrix were allowed to cocrystallize under ambient conditions. Matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) mass spectrometry was performed with an Applied Biosystems Voyager DEPro instrument equipped with a 20-Hz 337-nm nitrogen laser (Applied Biosystems, Inc., Foster City, CA, USA). Negative ion spectra were acquired in the linear delayed extraction mode under optimized conditions using close-external calibration based on a commercial mixture of peptides (Applied Biosystems).

2.8. Tandem MS Analysis of Tryptic Peptides {#sec2.8}
-------------------------------------------

The desalted tryptic peptides from the phosphorylated AtPDCE1*α* S298A mutant protein were analyzed by nanospray quadrupole time-of-flight mass spectrometry (Q-TOF MS) using an Applied Biosystems/MDS Sciex (Foster City, CA, USA) QStar/Pulsar instrument fitted with a nanospray source (Proxeon Biosystems, Odense, Denmark). A stable spray was achieved at 750 V in the presence of nitrogen curtain gas for sample dissolved in acetonitrile/water/88% formic acid (500/490/10, V/V/V). Positive ion spectra were acquired in the profile MCA mode at a pulser frequency of 6.99 kHz. Collision-induced dissociation spectra (MS/MS) were acquired for peptides selected by the first quadrupole at low resolution (3--5 amu window) and fragmented in the collision quadrupole at appropriate nitrogen collision gas pressures and collision energy settings. Fragmented ions were assigned nomenclature according to \[[@B32]\].

2.9. Measurement of Catalytic Activity {#sec2.9}
--------------------------------------

The catalytic activity of WT AtPDC E1 and site-directed mutants was determined by assaying the decarboxylation of \[1-^14^C\] pyruvate (20 mCi/mmol, Perkin-Elmer, Boston, MA, USA) in the presence of 1.0 mM K~3~Fe(CN)~6~ as the electron acceptor \[[@B33]\]. Reactions were preincubated for 2 min at 30°C before adding 1 mM \[1-^14^C\] pyruvate and 1 *μ*g AtPDC E1. One unit of enzyme activity is 1 *μ*mol of CO~2~ released per min at 30°C. All of the data presented comprise a minimum of two biological replicates plus three technical replicates.

Kinetic constants were determined by measuring decarboxylation of pyruvate in the presence of 1.8 *μ*M K~3~Fe(CN)~6~. The lower concentration of K~3~Fe(CN)~6~ reduced the otherwise high and variable background values to near zero. A fixed variable concentration of pyruvate ranging from 50 to 900 *μ*M was used with 1 *μ*g AtPDC E1. Data were fitted to the appropriate equations using the program Origin 7 (OriginLab Corporation, Northampton, MA, USA). The *K*~*m*~ and *k*~cat~ values were determined from initial-rate measurements and fit to the equation *v* = (*k*~cat~ × S)/(*K*~*m*~ + S), where S = substrate concentration.

2.10. Bacterial Two-Hybrid Analysis {#sec2.10}
-----------------------------------

Interactions between AtPDK and AtPDC E1*α* were analyzed using the bacterial two-hybrid (B2H) system (BacterioMatch I, Stratagene, La Jolla, CA, USA). Primers DDR471 and DDR472 were used to amplify WT AtPDK \[[@B29]\], while primers DDR473 and DDR474 were used to amplify both WT and mutant forms of E1*α*. The AtPDK sequence was cloned into pBT, and the AtE1*α* constructs were cloned into pTRG. Pairs of constructs were used to cotransform the *E. coli* Bacterio-Match I reporter strain. Selection was on Luria-Bertani agar containing 250 *μ*g/mL carbenicillin, 12.5 *μ*g/mL tetracycline, 34 *μ*g/mL chloramphenicol, and 50 *μ*g/mL kanamycin. Cells selected by antibiotic screening were additionally screened on LB plates containing 80 *μ*g/mL X-gal plus 0.2 mM *β*-galactosidase inhibitor (to inhibit endogenous *β*-galactosidase). Interactions between PDK and the E1*α* mutants were quantified by measuring *β*-galactosidase activity \[[@B34], [@B35]\]. The microplate spectrophotometric assay uses o-nitrophenyl-*β*-D-galactoside as the substrate.

3. Results {#sec3}
==========

3.1. In Silico Analysis of the E1*α* Active-Site Loop {#sec3.1}
-----------------------------------------------------

The active-site loop is a structural feature critical for both catalysis by E1 and phosphorylation of E1 by PDK. Overall, there is 50% sequence identity among the amino acid residues that comprise the active-site loop of diverse members of the *α*-ketoacid dehydrogenase family ([Figure 1(a)](#fig1){ref-type="fig"}). Two of the conserved residues were targeted in this study, Asp295 and Gly297. Located three residues C-terminal of phosphorylation site 1 (Ser292), Asp295 is the only acidic residue in proximity to this phosphorylation site. It is entirely conserved among *α*-ketoacid dehydrogenase sequences.

The primary sequence of AtPDC E1*α* was threaded through the crystal structure of HsE1*α* \[[@B16]\]. The resulting model indicates that Asp295 protrudes into the loop and can interact with His291 and Tyr300 ([Figure 1(b)](#fig1){ref-type="fig"}). The results from *in silico* mutagenesis of Asp295 indicate that these interactions would be disrupted if the hydrophilic side chain was replaced with an uncharged polar residue, that is, D295N. In the D295A and D295L mutants, interactions with His291 and Tyr300 would be completely abolished. The active-site loop is a highly charged region. If Asp295 plays a structural role in maintaining the structure of the loop, the mutations would disrupt substrate binding and/or interaction with AtPDK.

Of the five residues proximal to Ser292, Gly297 is conserved in eukaryotic PDC sequences, but not in those of the BCKDC. Since Gly297 is not in the immediate vicinity of Ser292, mutation would not be expected to directly affect phosphorylation of E1 but might still be involved with either presentation of the phosphorylation site to the kinase-active site or catalysis. The corresponding position in BCKDC contains a Ser residue suggesting that a small residue at this position may be sufficient for the structural conformation of the active-site loop. *In silico*, the G297D and G297S mutants do not affect the N-terminal interactions of Asp295 but induce an additional interaction with Arg301 ([Figure 1(c)](#fig1){ref-type="fig"}).

3.2. Expression of Recombinant AtPDCE1 {#sec3.2}
--------------------------------------

A two-plasmid approach was employed for expressing high yields of correctly assembled and fully active *α*~2~*β*~2~ heterotetrameric AtPDC E1 in *E. coli*. Expression of only the AtPDC E1*α* or E1*β* subunits individually invariably yielded only insoluble subunits ([Figure 2(a)](#fig2){ref-type="fig"}), while coexpression of the *α*- and *β*-subunits resulted in a substantial amount of soluble protein ([Figure 2(b)](#fig2){ref-type="fig"}). Immobilized metal affinity chromatography was used to purify recombinant AtPDC E1; analysis of the purification steps by SDS-PAGE is shown in Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}. The co-occurrence of *α*- and *β*-subunits was verified by immunoblotting ([Figure 2(d)](#fig2){ref-type="fig"}). Based upon visual examination of Coomassie Blue-stained SDS gels, it was estimated that final preparations of AtPDC E1 were \~95% pure.

To confirm the assembly of heterotetrameric AtPDC E1, the purified protein was subject to size-exclusion chromatography. Most recombinant protein eluted from the Sepharose 12 column at a position corresponding to an *M~r~* value of 160,000, which is what would be expected for an *α*~2~*β*~2~ heterotetramer. The far-UV CD spectra of the E1 proteins indicated no significant changes in secondary structure between WT AtPDC E1 and any of the site-directed mutants (data not presented).

3.3. Catalytic Activity of Recombinant AtPDC E1 {#sec3.3}
-----------------------------------------------

The specific activity values for the WT and mutant forms of AtPDC E1 are shown in [Table 1](#tab1){ref-type="table"}. The activity of the S292A mutant was reduced by 25%, while there was no change in the activity of the S298A mutant. In contrast, the activities of the S292D and S292D/S298A mutants were reduced by \>90%. The activities of the G297D and G297S mutants were reduced by 25 to 30%, while those of the D295A and D295N mutants were reduced by 60%. The D295L mutant protein was essentially inactive (1% residual activity).

The kinetic parameters of WT and the mutants, using pyruvate as the variable substrate, are shown in [Table 2](#tab2){ref-type="table"}. The *k*~cat~ values for the D295A and D295N mutants were reduced \~70%. The *K*~*m*~ pyruvate values for the D295A and D295N mutants were increased 4- to 6-fold compared with WT AtE1. The *k*~cat~ value for the G297D mutant was reduced by 50% without any change in *K*~*m*~ pyruvate. In these mutants, the catalytic efficiency (*k*~cat~/*K*~*m*~) was reduced by 3.5 to 35-fold, reduction that, although significant, is modest for the changes expected on mutation of residues directly involved in substrate binding and/or catalysis.

3.4. Phosphorylation of AtPDC E1 In Vitro {#sec3.4}
-----------------------------------------

Incubation of WT AtPDC E1 with recombinant AtPDK using 200 *μ*M \[*γ*-^32^P\] ATP resulted in the phosphorylation of a single polypeptide species ([Figure 3(a)](#fig3){ref-type="fig"}, lane 1). To analyze regulatory phosphorylation site 1 of AtPDC E1, three different mutants were constructed. The S292A mutant targets the conserved phosphorylation site 1, while the S298A mutant targets potential phosphorylation of the putative site 2. The S292D/S298A double mutant was constructed to mimic phosphorylation of AtPDC E1*α* Ser292 in the absence of a residue that could be phosphorylated at site 2.

Incubation of the mutant proteins with recombinant AtPDK plus 200 *μ*M \[*γ*-^32^P\] ATP resulted in phosphorylation of a single polypeptide species for the S298A mutant ([Figure 3](#fig3){ref-type="fig"}, lane 3). There were only trace amounts of phosphate incorporated into the S292A mutant (2% of WT) and into the S292D/S298A double mutant (1% of WT).

3.5. Analysis of the Phosphorylated AtPDC E1*α* S298A Mutant by Mass Spectrometry {#sec3.5}
---------------------------------------------------------------------------------

To verify that Ser292 was the site phosphorylated *in vitro*, the S298A mutant was phosphorylated with recombinant AtPDK plus unlabeled ATP, then subjected to in-gel tryptic digestion. The MALDI-TOF MS analysis of the tryptic peptides revealed an ion at M-H^−^ 1656.9 Da, which corresponds to the phosphopeptide Tyr286-Arg301 ([Figure 4(a)](#fig4){ref-type="fig"}). This was the only peptide detected by negative ion nanospray QqTOF precursor ion analysis that yielded the diagnostic fragment ion for phosphopeptides, 78.96 Da (the PO~3~^−^ ion). The sequence of this peptide was confirmed by positive ion nanospray QqTOF tandem MS analysis of the triple-charge ion at 553.55 Da in the peptide mixture ([Figure 4(b)](#fig4){ref-type="fig"}). The assignment of phosphate to Ser292 is supported by the presence of fragment ions b5^+^ (662.25 Da), b6^+^ (793.23 Da), and a complete y-ion series including y10^+^ (1164.41 Da). The most plausible interpretation of these data is that the Tyr286-Arg301 tryptic peptide is phosphorylated at Ser292. Tandem MS analyses of the double-charge ion at 829.8 Da and the triple-charge ion for the Met-oxidised form of the peptide at 558.9 Da provided additional evidence for phosphorylation of Ser292 (data not shown).

3.6. Phosphorylation of the Asp295 and Gly297 Mutants {#sec3.6}
-----------------------------------------------------

Comparison of WT and mutant AtPDC E1 proteins incubated with AtPDK for 90 min showed substantial differences in phosphorylation (Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}). In comparison with WT E1, phosphorylation of the D295A and D295N mutants was reduced by 92 and 83%, respectively, while phosphorylation of the D295L mutant was abolished (\~3% residual phosphorylation) ([Figure 5(a)](#fig5){ref-type="fig"}). In contrast, phosphorylation of the G297D and G297S mutants was little affected, being reduced 9 and 13%, respectively.

The data in [Figure 5(c)](#fig5){ref-type="fig"} show a time-dependent increase in phosphorylation of the G297D mutant, similar to that seen with the WT protein. In contrast, the low-level phosphorylation in the D295A and D295N mutant proteins did not increase with an increase in time.

3.7. B2H Analysis of Protein Interactions {#sec3.7}
-----------------------------------------

Interaction between PDK and E1 in our reconstituted *in vitro* system comprises a multistep sequence including recognition, binding, and phosphotransfer. We used the B2H synthetic genetic system to test the possibility that reduced phosphorylation of the AtPDC E1*α* D295A and D295N mutants was due to impaired binding of PDK. In these assays, protein interaction is quantified using the *β*-galactosidase reporter. Interactions between AtPDK and the mutant forms of AtPDC E1*α* were slightly reduced relative to WT E1*α* ([Figure 6](#fig6){ref-type="fig"}). It does not appear, however, that these small decreases in protein interaction are adequate to explain the large decreases in phosphorylation ([Figure 5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Two approaches were used previously to express recombinant plant mitochondrial PDC E1. Staphylococcal protein A-based vectors were constructed to direct secretion of the E1*α* and E1*β* subunits of *P. sativum*pyruvate dehydrogenase from separate strains of *B. subtilis* \[[@B22]\]. A bipartite vector was designed for simultaneous expression of E1*α* and E1*β* subunits in the cytoplasm of *P. pastoris*, but very low yields were the result of an unfavorable codon-usage bias \[[@B23]\]. While useful for analytical studies of E1 assembly, these systems yielded too little protein for detailed biochemical characterizations.

The envisioned analyses necessitated development of a method for heterologous expression and rapid purification of active, correctly folded and assembled recombinant AtPDC E1. The *E. coli* coexpression strategy routinely yielded \~8 mg of purified E1 per 500 mL, and more than 90% of this was assembled into heterotetramers. Catalytic activity was seemingly not influenced by the N-terminal His~6~-tag. When individually expressed at high levels neither subunit was soluble, suggesting that correct folding and assembly of large amounts of the heteromeric enzyme require the simultaneous presence of both subunits. Complexity in the folding and assembly pathway was not unexpected based upon previous reports \[[@B22], [@B23], [@B36], [@B37]\] and the reported participation of the GroE chaperonins \[[@B38]--[@B40]\].

Recombinant tetrameric AtPDC E1 catalyzed decarboxylation of pyruvate in the presence of high (1.0 mM) and low (1.8 *μ*M) concentrations of the artificial electron acceptor K~3~Fe(CN)~6~ (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). The specific activity of the recombinant enzyme was 0.32 *μ*mol min^−1^ mg^−1^ protein in assays containing 1 mM K~3~Fe(CN)~6~. This is \~2-fold higher than the values reported for recombinant HsPDC E1 \[[@B41]\] or native *E. coli* E1 \[[@B42]\] under similar assay conditions. The *K*~*m*~ pyruvate value for recombinant AtPDC E1 is similar to that of native pea mitochondrial PDC \[[@B43]\] but cannot be compared directly because of differences in assay procedures. There are currently no literature *k*~cat~ values for recombinant E1 proteins.

The catalytic activity of the AtPDC E1 S292A mutant was reduced by 26% ([Table 1](#tab1){ref-type="table"}), which is essentially identical to the effect previously reported for HsPDC E1 \[[@B41]\]. The activity of the AtPDC E1 S292D/S298A double mutant was reduced by 90% ([Table 1](#tab1){ref-type="table"}). Replacement of the HsPDC E1 site 1 Ser residue with the P-Ser mimic Glu reduced decarboxylase activity but abolished PDC activity. This result agrees with the previous observations that phosphorylation has a more pronounced effect on reductive acetylation than on substrate binding \[[@B42], [@B44]\].

Recombinant AtPDC E1 was efficiently phosphorylated*in vitro* by AtPDK. One mole of phosphate was incorporated per mol of subunit dimer. ([Figure 3](#fig3){ref-type="fig"}). The slight ^32^P incorporation on the S292A mutant and the unaffected phosphorylation level of the S298A mutant catalyzed by AtPDK suggested that only Ser292 is phosphorylated in our assay condition ([Figure 3](#fig3){ref-type="fig"}). Analysis of the S298A mutant by QqTOF tandem MS verified phosphorylation of only Ser292 ([Figure 4](#fig4){ref-type="fig"}). Our finding that only site 1 is phosphorylated with the reconstituted minimum *A. thaliana* system is in agreement with results obtained using the recombinant human proteins \[[@B45]\] and validate use of the plant system for further mechanistic studies.

There is no reason to believe that the enzymatic mechanism is somehow different in the absence/presence of E2. While the rate of E1 phosphorylation by PDK is higher in the presence of E2 (and higher yet with PDC) \[[@B46]\], this stimulation is due to a direct kinetic effect; that is, ADP disassociates faster from PDK when it is bound to E2 \[[@B47]\]. Our results are consistent with a previous study, using two-dimensional separation of phosphoproteins from potato mitochondria followed by MS analysis, which identified Ser292 as the only residue phosphorylated \[[@B48]\]. While phosphorylation of only site 1 was expected with the minimum *in vitro* system, multi-site phosphorylation remains a possibility upon addition of E2 or more likely as PDC.

Phosphorylation of Ser292 was affected considerably by changes to Asp295, being reduced in the order D295N \< D295A \< D295L ([Figure 5(a)](#fig5){ref-type="fig"}). Interaction between E1*α* and PDK is a multistep process that involves recognition of the phosphorylation-site region, docking of the PDK with this region, and subsequent transfer of the phosphoryl group. It is unlikely that the major reduction in phosphorylation of these mutants was due to inhibition of PDK binding to E1, because there was no significant reduction of interaction between AtPDK and the D295N or D295A mutants ([Figure 6](#fig6){ref-type="fig"}). It is logical that the reduction in phosphorylation of the active-site loop mutants is due to disruption of the transfer of the *γ*-phosphate from ATP to E1*α* Ser292, possibly the result in ordering or positioning of the active-site loop.

Some protein Ser/Thr kinases have an affinity for amino acids with acidic, basic, or hydrophobic functional groups located at defined positions N- or C-terminal to the phosphorylation site \[[@B49]\]. Our results are similar to an earlier study employing synthetic peptides as substrates for PDK. In those studies, peptides with the D295N substitution were poorer substrates for bovine PDK \[[@B8]\]. The Asp295 residue is one of a group of charged residues that form an H-bonding network that stabilizes the active-site loop \[[@B50]\], making it accessible to the lipoyl domain of E2. Perturbations in this network affect substrate channeling, and phosphorylation is believed to promote this disorder \[[@B44], [@B50]\]. Based on the results from *in silico* mutagenesis, we hypothesize that interactions with His291 and Tyr300 would be disrupted if Asp295 were substituted ([Figure 1(b)](#fig1){ref-type="fig"}). Even substitution with Glu would be predicted to abolish the H-bond with His291, although we did not test this experimentally. The reduced phosphorylation seen with all changes to Asp295 is consistent with the proposal that altering the acidic residue C-terminal to Ser292 destabilizes the structure of the active-site loop. Alternatively, it is possible that conservation of Asp295 is part of a mechanism that maintains the active-site loop disordered and provides access to Ser292.

Changes to Asp295 have been reported to have pleiotropic effects on phosphorylation of E1. Phosphorylation of RnBCKDC E1 was not affected by mutagenesis of Asp295 \[[@B18]\], but was inhibited by mutagenesis of Arg288, which corresponds to Arg285 of AtPDC E1*α*. In contrast, the same mutations of HsBCKDC E1 did not inhibit phosphorylation \[[@B50]\]. The D296E mutant in HsPDC E1*α* was still phosphorylated, although in these analyses the effect of phosphorylation was determined indirectly by measuring the decrease in activity of an already catalytically compromised mutant protein \[[@B51]\].

The catalytic response to the D295A change has been studied in other systems but using a similar assay method, which simplifies comparisons. In the case of AtPDC E1, the catalytic activities of the D295A and D295N mutants were reduced considerably ([Table 1](#tab1){ref-type="table"}). The *K*~*m*~ pyruvate values of these mutant proteins were increased 5-fold, while the *k*~cat~ decreased by \>70%. The response of the HsBCKDC E1 to the D295A mutation was essentially the same as with AtPDC E1 in terms of catalytic activity and *k*~cat~ values; however, in that instance, the *K*~*m*~ pyruvate was unaffected \[[@B50]\]. In a case of extreme contrasts, this D \> A mutation of RnBCKDC E1 yielded a catalytically dead protein \[[@B18]\], while the activity of the *B. stearothermophilus* PDC E1*α* actually increased 3-fold (and the *K*~*m*~ pyruvate value by 10-fold) \[[@B17]\]. The modest but consistent reduction in *k*~cat~ and *k*~cat~/*K*~*m*~ values seen with the AtPDC E1 mutants are in agreement with the proposal that Asp295 stabilizes the active-site loop conformation. The differences seen with ostensibly closely related enzymes suggest small or subtle differences in loop structure or stability. In the case of the more structurally distant *E. coli* PDC E1, the H-bonding loop-stabilizing pattern also involves nonconserved residues \[[@B52]\].

Binding of the TPP cofactor confers an ordering to the E1*α* active-site loop. When the site 1 Ser residue is phosphorylated, the presence of the phosphoryl group prevents this ordering \[[@B52]\]. The mechanism involved has been referred to as a "steric clash" between the P-Ser at site 1 and a nearby Ser residue which then nullifies a hydrogen-bonding network \[[@B44]\]. Some of the effects that we have seen with the AtPDC E1*α* Asp295 mutants could be explained by this same mechanism. The disordered phosphorylation loops impede the binding of lipoyl domains of the PDC E2-core to E1 \[[@B44]\]. The importance of structural order/disorder on protein phosphorylation is the subject of much current attention \[[@B53], [@B54]\].

The conserved Gly297 residue does not have an obvious role in the phosphorylation of the site 1 Ser residue. Phosphorylation was not affected in either the G297S mutant, where residue size is similar, or the G297D mutant which represents a drastic change ([Figure 5(b)](#fig5){ref-type="fig"}). These results seem to indicate that the residue present in this position is not directly involved with either formation or stabilization of the active-site loop structure. The reduction in *k*~cat~, without any change in *K*~*m*~ pyruvate, suggests that replacing Gly297 with a polar residue, such as Asp, might be interfering with interactions between Tyr-300 and the carboxyl group of pyruvate, either directly or via steric hindrance.

Since all of the mutant subunits assembled into heterotetramers, neither Asp295 nor Gly297 is critical for subunit association. Moreover, the far-UV CD spectra of the mutant proteins were not distinguishable from the spectra obtained for the WT protein (data not presented), indicating that no gross structural perturbations occurred as a result of the mutations.

The defined *in vitro* system that we have developed is suitable for additional detailed analyses of the mechanism of regulatory phosphorylation of the plant mitochondrial PDC. Future studies will include the recombinant plant E2 proteins and domains and will address the differences in behavior between the mono- and dilipoyl forms of this core component of the PDC \[[@B55]\].
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At:

:   *Arabidopsis thaliana*

BCKDC:

:   Branched-chain *α*-ketoacid dehydrogenase complex

B2H:

:   Bacterial 2-hybrid

E1:

:   *α*-ketoacid dehydrogenase/decarboxylase

E1*α*:

:   *α*-subunit of E1

Hs:

:   *Homo sapiens*

PDC:

:   Pyruvate dehydrogenase complex

PDK:

:   Pyruvate dehydrogenase-kinase

Rn:

:   *Rattus norvegicus*

WT:

:   Wild type.

![Molecular modeling and in silico mutagenesis of the active-site loop of AtPDC E1*α*. (a) Alignment of residues in the active-site loop of *α*-ketoacid dehydrogenase E1*α* sequences. Numbering is based upon the *A. thaliana* PDC E1*α* sequence. The plant mtPDC sequence is identical in *Pisum sativum*, *A. thaliana*, *Glycine max*, *Lycopersicon esculentum*, *Solanum tuberosum*, *Beta vulgaris*, *Nicotiana tabacum*, *Populus hybrida*, *Lotus corniculatus*, *Medicago truncatula*, *Zea mays*, and *Oryza sativum*. The mammalian PDC sequence is identical in *Rattus norvegicus*, *Mus musculus*, and *Homo sapiens*. The nematode PDC sequence is identical in *Ascaris suum* and *Caenorhabditis elegans*. The yeast PDC sequence is identical in *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, and *Kluyveromyces lactis*. Bacterial PDC sequences are identical from *Bacillus subtilis* and *Bacillus stearothermophilus*. The mammalian BCKDC sequence is identical in *H. sapiens*, *M. musculus*, and *Ovis aries*. The bacterial BCKDC sequence is from B. subtilis. The carats denote the Asp and Gly residues targeted in this study. The red underlined Ser residues correspond to mammalian pyruvate dehydrogenase phosphorylation sites 1 and 2 and mammalian BCKDC phosphorylation site 2. (b) The consensus active-site loop primary sequence presented as output from the WebLogo program \[[@B56]\]. (c) Carbon-alpha trace from modeling of residues His-291 to Arg-301 in the active site loop of AtE1*α*. The same colors have been used for each residue in all panels. Hydrogen bonds are indicated with green dashed lines. Traces were built using Swiss-PDB viewer (version 3.7).](ER2011-939068.001){#fig1}

![Expression and purification of *A. thaliana* pyruvate dehydrogenase. (a) Bacterial expression of AtPDC E1*α* and E1*β*. An SDS gel of total proteins from uninduced *E. coli* BL21 (DE3) cells containing pT7-7:AtE1*α*; insoluble (I.F.) and soluble (S.F.) fractions from induced cells; total proteins from uninduced cells containing pET28:AtE1*β*; insoluble and soluble fractions from induced cells. The positions of AtPDC E1*α* and E1*β* are indicated by arrows. (b) An SDS gel of a typical 2-plasmid AtPDC E1 *α* plus *β* coexpression and purification profile using the HiTrap chelating column charged with 0.1 M NiSO~4~; insoluble fraction, soluble fraction, flow through (F.T.). The position of AtPDC E1*β* in the soluble fraction is indicated by an arrow. (c) A Coomassie-stained SDS gel of AtPDC E1 after immobilized metal affinity chromatography. (d) Immunoblot analysis of AtPDC E1. The E1*α* subunit was detected with monoclonal anti-E1*α* antibodies, and the E1*β* subunit was detected with monoclonal anti-FLAG antibodies. The positions of molecular mass markers are indicated on the left for (a) and (b). All gels (except the Immunoblot) were stained with Coomassie Blue.](ER2011-939068.002){#fig2}

![Phosphorylation of recombinant AtPDC E1 by recombinant AtPDK. (a) Autoradiograph of the *in vitro* phosphorylation of wild-type (WT) AtE1*α*, and the S292A and S298A mutants, by recombinant AtPDK. One *μ*g of E1 was incubated with 0.25 *μ*g PDK and 200 *μ*M \[*γ*-^32^P\]ATP, at 30°C for 90 min. When the film was developed after 3 h, phosphorylation of the WT and the S298A proteins was visible, while no phosphorylation was observed for the S292A and the double mutants. Furthermore, no phosphorylation of the S292A or double mutants was observed when the same film was developed after 16 h. (b) Phosphorylation of the mutant proteins relative to WT. The 100% phosphorylation value of WT was 1.0 ± 0.04 *μ*mol ^32^P mol AtPDC E1^−1^. Data are the mean values from at least three separate determinations ± SEM.](ER2011-939068.003){#fig3}

![Analysis of the AtPDC E1*α* S298A mutant phosphorylation site by mass spectrometry. (a) MALDI-TOF MS analysis of tryptic peptides from the AtPDC E1*α* S298A mutant. The 1656.9 *m/z* ion corresponds to the phosphopeptide Tyr286 to Arg301. (b) Fragmentation of the *m/z* 1656.9 peptide by nanoelectrospray tandem MS. Fragment ion spectrum from the triple-charge molecular ion at *m/z* 553.55. The ions b5^+^ (662.25), b6^+^ (793.23), and y10^+^ (1164.41) indicate P-Ser292. The asterisks mark the fragment ions from the S298A-methylated peptide that was also present in the parent ion envelope at (M + 3H)^3+^ of 553.95 Da. (c) Expanded spectrum of the y10^+^ ion.](ER2011-939068.004){#fig4}

![Phosphorylation of AtPDC E1*α* active-site loop mutants by AtPDK. (a) (i) Autoradiograph comparing phosphorylation of WT AtPDC E1 and the Asp295 mutant. (a) (ii) Autoradiograph comparing phosphorylation of WT AtPDC E1 and the Gly297 mutant. One *μ*g each of the WT and mutant proteins was incubated with 0.25 *μ*g AtPDK and 200 *μ*M \[*γ*-^32^P\]ATP at 30°C for 90 min. In each case the entire reaction mixture was loaded onto the gels. After electrophoresis, all gels were exposed to film for 3 h. (b) Relative (to WT) phosphorylation of the Asp295 and Gly297 mutants is indicated. Data are mean values from at least three separate determinations ± SEM. The value for 100% of WT phosphorylation was 0.7 ± 0.02 *μ*mol ^32^P *μ*mol AtPDC E1^−1^. (c) Time-course of phosphorylation. The WT AtPDC E1 (▴), and the G297D (□), D295A (○), and D295N (`♦`) mutant proteins, were phosphorylated as described in (a). Reactions volumes were 100 *μ*L. Samples of 20 *μ*L were removed at each time point, mixed with SDS-sample buffer, heated, and then resolved by SDS-PAGE.](ER2011-939068.005){#fig5}

![Quantitative analysis of interactions between AtPDC E1 and AtPDK. Quantitative B2H analysis was used to study interaction between WT AtPDC E1*α*, the D295A, and D295N mutants and AtPDK. The AtPDK sequence was cloned into the Stratagene B2H vector pBT, while the E1*α* sequences were cloned into pTRG. After selection, protein interactions were quantified using the *β*-galactosidase reporter. The value for 100% of WT activity was 3 *μ*mol min^−1^ 1.0 A600^−1^. Data are the mean ± SEM from two separate experiments, each assay conducted in triplicate.](ER2011-939068.006){#fig6}

###### 

The specific activities of WT and mutant AtPDC E1 proteins were determined by assaying the decarboxylation of \[1-^14^C\] pyruvate in the presence of 1.0 mM K~3~Fe(CN)~6~ as the electron acceptor.

  Enzyme        Specific activity (units/mg)   \%
  ------------- ------------------------------ -----
  WT AtPDCE1    0.32 ± 0.01                    100
  S292A         0.24 ± 0.06                    74
  S298A         0.31 ± 0.02                    97
  S292D         0.02 ± 0.03                    6
  S292D/S298A   0.03 ± 0.03                    9
  D295A         0.12 ± 0.01                    37
  D295N         0.12 ± 0.01                    37
  D295L         0.003                          1
  G297D         0.24 ± 0.03                    75
  G297S         0.22 ± 0.04                    68

###### 

Kinetic parameters of WT AtPDC E1 and site-directed mutants. Activities were determined by assaying decarboxylation of \[1-^14^C\] pyruvate in the presence of 1.8 *μ*M K~3~Fe(CN)~6~.

  Enzyme   *K*~*m*~ pyruvate (*μ*M)   *k*~cat~ (s^−1^)   *k*~cat~/*K*~*m*~ (*μ*M^−1^ s^−1^)
  -------- -------------------------- ------------------ ------------------------------------
  WTAtE1   45 ± 18                    159 ± 14           3.5
  D295A    178 ± 108                  52 ± 12            0.3
  D295N    257 ± 144                  38 ± 10            0.1
  G297D    66 ± 24                    70 ± 7             1.0
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